Increased expression of UBE2C has been observed in various solid cancers including breast cancer, non-small cell lung cancer, bladder cancer, and ovarian cancer [18–22] As for ESCC, a recently published study has indicated that elevated level of UBE2C is associated with a more advanced clinical stage and worse prognosis [23]. Here, UBE2C is linked to non-small cell lung carcinoma.